TREM2作为IL-34的受体抑制小鼠急性髓系白血病
研究在小鼠模型中发现,敲除破骨细胞Tsc1可释放高水平IL-34,后者直接结合TREM2受体,经Rasal3磷酸化并抑制ERK1/2信号,诱导AML细胞分化并阻止疾病进展;AML患者中TREM2下调且与不良预后相关。
要点
- 破骨细胞Tsc1缺失小鼠的AML移植瘤发展受抑制,与IL-34释放增多有关。
- IL-34不依赖已知受体,直接结合TREM2抑制AML,TREM2缺陷AML细胞对IL-34抵抗。
- AML患者TREM2表达下调且与不良预后相关。
核心结论
- 本研究鉴定TREM2为IL-34的新受体,IL-34-TREM2轴可克服AML分化阻滞。
研究设计与样本
- 研究使用Tsc1缺失破骨细胞小鼠、IL-34缺陷小鼠及多种临床前模型进行实验。
主要发现
- Tsc1缺失破骨细胞释放高水平IL-34,高效诱导AML细胞分化并阻止AML进展。
- IL-34缺陷小鼠中AML发展加速。
- IL-34不依赖已知受体而直接结合TREM2,TREM2缺陷的AML细胞和正常髓系细胞对IL-34治疗抵抗。
- IL-34-TREM2结合快速磷酸化Rasal3并灭活ERK1/2信号,抑制AML细胞增殖并刺激分化。
- AML患者中TREM2下调且与不良预后相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The bone marrow microenvironment supports leukocyte mobilization and differentiation and controls the development of leukemias, including acute myeloid leukemia (AML). Here, we found that the development of AML xenotransplants was suppressed in mice with osteoclasts tuberous sclerosis 1 (Tsc1) deletion. Tsc1-deficient osteoclasts released a high level of interleukin-34 (IL-34), which efficiently induced AML cell differentiation and prevented AML progression in various preclinical models. Conversely, AML development was accelerated in mice deficient in IL-34. Interestingly, IL-34 inhibited AML independent of its known receptors but bound directly to triggering receptor expressed on myeloid cells 2 (TREM2), a key hub of immune signals. TREM2-deficient AML cells and normal myeloid cells were resistant to IL-34 treatment. Mechanistically, IL-34-TREM2 binding rapidly phosphorylated Ras protein activator like 3 and inactivated extracellular signal-regulated protein kinase 1/2 signaling to prevent AML cell proliferation and stimulate differentiation. Furthermore, TREM2 was downregulated in patients with AML and associated with a poor prognosis. This study identified TREM2 as a novel receptor for IL-34, indicating a promising strategy for overcoming AML differentiation blockade in patients with AML.
引用
- Xie X, Zhang W, Xiao M, et al. TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice. Blood. 2023. PMID: 37001042. doi:10.1182/blood.2022018619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。